Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Getinge AB    GETI B   SE0000202624

GETINGE AB

(GETI B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Getinge : launches NICCI - the latest innovation in Advanced Hemodynamic Monitoring

10/26/2020 | 08:01am EST

NICCI is Getinge's latest innovation in Advanced Hemodynamic Monitoring, providing continuous and noninvasive hemodynamic insights to reduce the risk of severe complications for patients with low blood pressure.

[image]

Blood pressure is one of the most important variables evaluated during almost every surgical intervention, but recent studies [1] show that fluctuations in blood pressure may be missed due to standard intermittent readings.

These occurring blood pressure drops, called hypotensions, result in complications which can get severe and even life threatening. They can however be reduced by continuous, noninvasive blood pressure monitoring. That's why Getinge launches NICCI, the latest innovation in Advanced Hemodynamic Monitoring, providing continuous and noninvasive hemodynamic insights. It has already been awarded with the Red Dot Award 2020 for its design.

"With NICCI, hemodynamic monitoring has never been easier. While measuring continuously and non-invasively, NICCI provides a complete picture of the patient's individual hemodynamic status - ensuring the medical staff that they never miss a beat," says Clemens Brühl, Head of Product Management Advanced Patient Monitoring at Getinge.

With dynamic parameters like cardiac index (CI), stroke volume variation (SVV) and pulse pressure variation (PPV) NICCI guides individual treatment decisions for example related to Goal Directed Fluid Therapy (GDFT).

 "It has a sensor that comes in three sizes, containing two finger cuffs that perform an automatically alternating continuous measurement from one finger to the other after no more than an hour. This enables continuous use of NICCI for up to 72 hours," explains Clemens Brühl.

He adds:

"The easy click mechanism allows a fast setup and there are smart design elements such as an integrated cable storage and quick access keys to allow a simple handling."

NICCI is based on the Continous Noninvasive Arterial Pressure Technology (CNAP).

NICCI allows the anesthesiologist to assess the patients' hemodynamic status even before induction of anesthesia and after surgery. Main application area is before, during and after surgery as well as in post-operative care units, but also emergency rooms and cath-labs.

Learn more about NICCI >> (https://www.getinge.com/int/product-catalog/nicci-technology/)

Discover facts and figures on hypotension >> (https://www.getinge.com/int/insights-results/optimized-clinical-treatment/advanced-patient-monitoring/reduce-intraoperative-hypotension/hypotension-facts-and-figures)

 

The availability of NICCI depends on regional regulatory approval status. If you have questions, please reach out to your local Getinge representative.

Source:

[1] https://www.getinge.com/int/insights-results/optimized-clinical-treatment/advanced-patient-monitoring/reduce-intraoperative-hypotension/hypotension-facts-and-figures

Media contact:

Anna Appelqvist, Vice President Corporate Communications
Phone: +46 (0)10 335 5906
E-mail: anna.appelqvist@getinge.com  

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

https://news.cision.com/getinge/r/getinge-launches-nicci---the-latest-innovation-in-advanced-hemodynamic-monitoring,c3221940

https://mb.cision.com/Main/942/3221940/1323376.pdf

https://news.cision.com/getinge/i/getinge-nicci,c2842021

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about GETINGE AB
12/03GETINGE : introduces new inner racks for stainless steel DPTE® Beta Containers
PU
11/25ALERT : New purchases in the Investor Europe portfolio
11/16GETINGE : files lawsuit against insurer Moderna Försäkringar, Swedish branch of ..
PU
11/10GETINGE : is announcing a recall of HLS Set Advanced products
PU
11/10GETINGE : is announcing a recall of HLS Set Advanced products
AQ
11/06GETINGE : has acquired Quadralene, a manufacturer of decontamination products
AQ
10/28ALERT : New purchase in the Investor Europe portfolio
10/26GETINGE : launches NICCI – the latest innovation in Advanced Hemodynamic M..
PU
10/26GETINGE : launches NICCI - the latest innovation in Advanced Hemodynamic Monitor..
AQ
10/22GETINGE : Cost-efficient sterilization with Getinge's new steam sterilizer Solsu..
AQ
More news
Financials
Sales 2020 30 023 M 3 555 M 3 555 M
Net income 2020 3 125 M 370 M 370 M
Net Debt 2020 9 369 M 1 110 M 1 110 M
P/E ratio 2020 15,9x
Yield 2020 1,61%
Capitalization 49 571 M 5 873 M 5 870 M
EV / Sales 2020 1,96x
EV / Sales 2021 2,01x
Nbr of Employees 10 800
Free-Float 80,0%
Chart GETINGE AB
Duration : Period :
Getinge AB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GETINGE AB
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 218,92 SEK
Last Close Price 182,00 SEK
Spread / Highest target 51,1%
Spread / Average Target 20,3%
Spread / Lowest Target -29,7%
EPS Revisions
Managers
NameTitle
Mattias Sven Perjos President, Chief Executive Officer & Director
Johan Malmquist Chairman
Lars Sandström Chief Financial Officer
Carl Reinhold Adolf Bennet Vice Chairman
Johan Bygge Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GETINGE AB4.25%5 873
MASIMO CORPORATION61.03%14 013
NOVOCURE LIMITED54.53%13 256
ASAHI INTECC CO., LTD.16.09%9 100
PENUMBRA, INC.24.94%7 453
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.40.35%4 335